- Home
- Publications
- Publication Search
- Publication Details
Title
Toward the clinical development of synthetic immunity to cancer
Authors
Keywords
-
Journal
IMMUNOLOGICAL REVIEWS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-07-26
DOI
10.1111/imr.13245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single-cell spatial landscapes of the lung tumour immune microenvironment
- (2023) Mark Sorin et al. NATURE
- Single-cell spatial immune landscapes of primary and metastatic brain tumours
- (2023) Elham Karimi et al. NATURE
- Synapse-tuned CARs enhance immune cell anti-tumor activity
- (2023) Peter J. Chockley et al. NATURE BIOTECHNOLOGY
- Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy
- (2023) Simon Deycmar et al. Journal for ImmunoTherapy of Cancer
- Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
- (2023) John D. Klement et al. CANCER CELL
- Angiopoietin-2–Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma
- (2023) Ha-Ram Park et al. CANCER RESEARCH
- Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
- (2023) Maha K. Rahim et al. CELL
- TET2 guards against unchecked BATF3-induced CAR T cell expansion
- (2023) Nayan Jain et al. NATURE
- Co-opting signalling molecules enables logic-gated control of CAR T cells
- (2023) Aidan M. Tousley et al. NATURE
- GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
- (2023) Francesca Del Bufalo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells
- (2023) David Mai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
- (2023) Radwa Ewaisha et al. Frontiers in Bioengineering and Biotechnology
- HLA-independent T cell receptors for targeting tumors with low antigen density
- (2022) Jorge Mansilla-Soto et al. NATURE MEDICINE
- Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
- (2022) Louai Labanieh et al. CELL
- Modular design of synthetic receptors for programmed gene regulation in cell therapies
- (2022) Iowis Zhu et al. CELL
- CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma
- (2022) Nathan T. Schomer et al. CYTOTHERAPY
- Direct and indirect regulation of the tumor immune microenvironment by VEGF
- (2022) Yuqing Zhang et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Exhaustion of CAR T cells: potential causes and solutions
- (2022) Taku Kouro et al. Journal of Translational Medicine
- CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
- (2022) Rebecca C. Larson et al. NATURE
- Clinical relevance of tumour-associated macrophages
- (2022) Mikael J. Pittet et al. Nature Reviews Clinical Oncology
- Hurdles to breakthrough in CAR T cell therapy of solid tumors
- (2022) Faroogh Marofi et al. Stem Cell Research & Therapy
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
- (2022) Manali Kamdar et al. LANCET
- Macrophages as tools and targets in cancer therapy
- (2022) Alberto Mantovani et al. NATURE REVIEWS DRUG DISCOVERY
- Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
- (2022) Zinaida Good et al. NATURE MEDICINE
- Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis
- (2022) Le Qin et al. Nature Communications
- Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy
- (2022) Gyeyoung Choi et al. International Journal of Environmental Research and Public Health
- Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
- (2022) Alfonso R. Sánchez-Paulete et al. Cancer Immunology Research
- CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
- (2022) Paula Rodriguez-Marquez et al. Science Advances
- Synthetic cytokine circuits that drive T cells into immune-excluded tumors
- (2022) Greg M. Allen et al. SCIENCE
- Enhanced T cell effector activity by targeting the Mediator kinase module
- (2022) Katherine A. Freitas et al. SCIENCE
- Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning
- (2022) Kyle G. Daniels et al. SCIENCE
- Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
- (2022) Daniel B. Goodman et al. Science Translational Medicine
- Applying a clinical lens to animal models of CAR-T cell therapies
- (2022) Brynn B. Duncan et al. Molecular Therapy-Methods & Clinical Development
- CAR T cells in solid tumors: challenges and opportunities
- (2021) Faroogh Marofi et al. Stem Cell Research & Therapy
- Immunogenicity of CAR T cells in cancer therapy
- (2021) Dimitrios L. Wagner et al. Nature Reviews Clinical Oncology
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A chimeric GM-CSF/IL18 receptor to sustain CAR T-cell function
- (2021) Shannon Lange et al. Cancer Discovery
- Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis
- (2021) Sabina Kaczanowska et al. CELL
- Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
- (2021) Evan W. Weber et al. SCIENCE
- SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models
- (2021) Axel Hyrenius-Wittsten et al. Science Translational Medicine
- SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma
- (2021) Joseph H. Choe et al. Science Translational Medicine
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
- (2021) Alexander Bagaev et al. CANCER CELL
- Spatially organized multicellular immune hubs in human colorectal cancer
- (2021) Karin Pelka et al. CELL
- TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma
- (2021) Kyung-Eun Noh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
- (2021) Yajing Zhang et al. LEUKEMIA
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
- (2021) Jay Y. Spiegel et al. NATURE MEDICINE
- Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
- (2021) Alexander I. Salter et al. Science Signaling
- A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab
- (2021) Prasad S Adusumilli et al. Cancer Discovery
- Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
- (2021) Praveen Ramakrishnan Geethakumari et al. Current Hematologic Malignancy Reports
- Discovering dominant tumor immune archetypes in a pan-cancer census
- (2021) Alexis J. Combes et al. CELL
- Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism
- (2021) Honglin Jiang et al. GASTROENTEROLOGY
- A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
- (2021) Heng Mei et al. Journal of Hematology & Oncology
- CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
- (2021) Shaun Cordoba et al. NATURE MEDICINE
- Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
- (2021) Brooke Prinzing et al. Science Translational Medicine
- The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
- (2021) Astri Frafjord et al. Frontiers in Immunology
- Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
- (2020) Wenyan Zhong et al. BMC GENOMICS
- CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma
- (2020) Guangna Liu et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
- (2020) Lei Zhang et al. CELL
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
- (2020) Junyun Lai et al. NATURE IMMUNOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
- (2020) Eugenia Zah et al. Nature Communications
- The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
- (2020) Alireza Labani-Motlagh et al. Frontiers in Immunology
- IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
- (2020) Ting Zhou et al. NATURE
- Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
- (2020) Elisa Peranzoni et al. Frontiers in Immunology
- Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
- (2020) Vid Leko et al. CANCER CELL
- A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy
- (2020) Shannon K. Oda et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
- (2019) Shivani Srivastava et al. CANCER CELL
- CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
- (2019) Nicholas F. Kuhn et al. CANCER CELL
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers
- (2019) Andrew R. Haas et al. MOLECULAR THERAPY
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
- (2019) Patrick A. Baeuerle et al. Nature Communications
- Efficacy and Safety of CAR19/22 T-cell "Cocktail" Therapy in Patients with Refractory/ Relapsed B-Cell Malignancies
- (2019) Na Wang et al. BLOOD
- Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed/refractory acute lymphoblastic leukemia
- (2019) Cheng Qian et al. CLINICAL CANCER RESEARCH
- Mechanisms Controlling PD-L1 Expression in Cancer
- (2019) Jong-Ho Cha et al. MOLECULAR CELL
- Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells
- (2019) Iñaki Etxeberria et al. CANCER CELL
- PTPN 2 phosphatase deletion in T cells promotes anti‐tumour immunity and CAR T‐cell efficacy in solid tumours
- (2019) Florian Wiede et al. EMBO JOURNAL
- Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
- (2019) Jun Wei et al. NATURE
- Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Jiang Cao et al. AMERICAN JOURNAL OF HEMATOLOGY
- Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
- (2018) Jinyang Li et al. IMMUNITY
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
- (2018) Christopher C. Kloss et al. MOLECULAR THERAPY
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
- (2018) Keishi Adachi et al. NATURE BIOTECHNOLOGY
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
- (2018) Agne Taraseviciute et al. Cancer Discovery
- Chimeric antigen receptors that trigger phagocytosis
- (2018) Meghan A Morrissey et al. eLife
- CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity
- (2018) Gray Kueberuwa et al. Molecular Therapy-Oncolytics
- Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging
- (2018) Yury Goltsev et al. CELL
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
- (2018) Joseph A. Fraietta et al. NATURE
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Nonhuman Primates and Translational Research: Progress, Opportunities, and Challenges
- (2017) John D Harding ILAR JOURNAL
- Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains
- (2017) Daniel T. Harris et al. JOURNAL OF IMMUNOLOGY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- An oxygen sensitive self-decision making engineered CAR T-cell
- (2017) Alexandre Juillerat et al. Scientific Reports
- High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
- (2017) Sarah A. Richman et al. Cancer Immunology Research
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- Macrophages and Therapeutic Resistance in Cancer
- (2015) Brian Ruffell et al. CANCER CELL
- Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
- (2015) Ignazio Caruana et al. NATURE MEDICINE
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Precision cancer mouse models through genome editing with CRISPR-Cas9
- (2015) Haiwei Mou et al. Genome Medicine
- Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
- (2015) E. Wang et al. Cancer Immunology Research
- Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
- (2014) Luke A. Gilbert et al. CELL
- Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal
- (2014) J. S. Park et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Single Peptide-Major Histocompatibility Complex Ligand Triggers Digital Cytokine Secretion in CD4+ T Cells
- (2013) Jun Huang et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
- (2013) Sunitha Kakarla et al. MOLECULAR THERAPY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Influence of tumour micro-environment heterogeneity on therapeutic response
- (2013) Melissa R. Junttila et al. NATURE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
- (2011) E. K. Moon et al. CLINICAL CANCER RESEARCH
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
- (2010) John A. Craddock et al. JOURNAL OF IMMUNOTHERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
- (2010) H.-T. Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
- (2009) A. Di Stasi et al. BLOOD
- Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis
- (2008) Michele De Palma et al. CANCER CELL
- The use of GEM models for experimental cancer therapeutics
- (2008) A. Gopinathan et al. Disease Models & Mechanisms
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
- (2008) A. Kruschinski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation